PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.16%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-4.91%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
133.15%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
184.17%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
37.12%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
39.13%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
39.13%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.54%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.09%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.74%
Dividend reduction while AVGO stands at 7.69%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-66.82%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.09%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
98.72%
10Y revenue/share CAGR above 1.5x AVGO's 36.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
5.70%
5Y revenue/share CAGR under 50% of AVGO's 36.16%. Michael Burry would suspect a significant competitive gap or product weakness.
0.26%
3Y revenue/share CAGR under 50% of AVGO's 21.18%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
177.32%
10Y OCF/share CAGR under 50% of AVGO's 4123.37%. Michael Burry would worry about a persistent underperformance in cash creation.
-32.68%
Negative 5Y OCF/share CAGR while AVGO is at 4123.37%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.52%
Negative 3Y OCF/share CAGR while AVGO stands at 332.88%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
367.16%
Below 50% of AVGO's 1712.33%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-34.45%
Negative 5Y net income/share CAGR while AVGO is 1712.33%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-38.72%
Negative 3Y CAGR while AVGO is 215.58%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
54.13%
Equity/share CAGR of 54.13% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
33.19%
Equity/share CAGR of 33.19% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
24.41%
Below 50% of AVGO's 122.23%. Michael Burry suspects a serious short-term disadvantage in building book value.
846.73%
Dividend/share CAGR of 846.73% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
109.10%
Dividend/share CAGR of 109.10% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
73.43%
3Y dividend/share CAGR of 73.43% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
8.37%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-3.24%
Inventory is declining while AVGO stands at 7.22%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.81%
Negative asset growth while AVGO invests at 1.05%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.46%
Under 50% of AVGO's 4.09%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.05%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-1.41%
Our R&D shrinks while AVGO invests at 16.25%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
6.74%
SG&A growth well above AVGO's 8.16%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.